Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company that regularly issues news and updates about its inflammation and immunology pipeline targeting the innate immune system. This news page aggregates company press releases and third-party coverage related to INmune Bio’s DN-TNF platform, CORDStrom™ mesenchymal stromal cell platform, and INKmune® natural killer cell priming platform.
Readers can find updates on XPro™ (XPro1595, pegipanermin), a selective soluble TNF neutralizer that the company is developing for neurological diseases driven by chronic inflammation. Recent news has highlighted Phase 2 MINDFuL trial results in early Alzheimer’s disease with inflammatory biomarkers, neuroimaging analyses using advanced MRI techniques, and manuscript submissions to peer-reviewed journals. The company also reports on scientific presentations at conferences such as the Clinical Trials on Alzheimer’s Disease (CTAD) meeting and the Alzheimer’s Association International Conference.
News related to the CORDStrom™ cell therapy platform includes clinical and manufacturing milestones in recessive dystrophic epidermolysis bullosa (RDEB), such as completion of a blinded randomized trial, pilot-scale commercial manufacturing runs at a cell and gene therapy manufacturing center in the United Kingdom, and intellectual property developments. INmune Bio also issues updates on participation in industry events and panels focused on dermatologic rare diseases and cell therapy manufacturing.
For the INKmune® platform, news items cover progress in the CaRe PC Phase I/II trial in metastatic castration-resistant prostate cancer, including reports that the trial met its primary and certain secondary endpoints, safety observations, and biomarker findings related to NK cell activation. Corporate news, including financing transactions, management changes, and special stockholder meetings, is also disclosed through regular press releases and corresponding SEC filings. Investors and researchers can use this page to follow INMB news on clinical data, regulatory plans, manufacturing scale-up, and corporate developments.
INmune Bio Inc., a clinical-stage immunology company, has completed the first cohort and initiated the second cohort of a Phase 1/2 study of INKmune™ Natural Killer Cell Therapy for metastatic castration-resistant prostate cancer. The company is encouraged by the safety and efficacy of the therapy, with approval granted to proceed with the second dose level. Prof. Mark Lowdell Ph.D., CSO of INmune Bio, highlights the potential of INKmune to transform resting NK cells into cancer-killing cells, offering a promising therapy for prostate cancer patients.
FAQ
What is the current stock price of Inmune Bio (INMB)?
What is the market cap of Inmune Bio (INMB)?
